Rat Albumin Elisa Kit, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat albumin elisa kit/product/Hycult Biotech
Average 86 stars, based on 1 article reviews
Price from $9.99 to $1999.99
1) Product Images from "“Rogue” neutrophil-subset [DEspR+CD11b+/CD66b+] immunotype is an actionable therapeutic target for neutrophilic inflammation-mediated tissue injury – studies in human, macaque and rat LPS-inflammation models"
Article Title: “Rogue” neutrophil-subset [DEspR+CD11b+/CD66b+] immunotype is an actionable therapeutic target for neutrophilic inflammation-mediated tissue injury – studies in human, macaque and rat LPS-inflammation models
Journal: Frontiers in Immunology
Figure Legend Snippet: DEspR+ neutrophil-subset roles in LPS-induced tissue injury model. (A) Diagram of LPS-induced multi-organ encephalopathy rat model in hsICH-prone rats. Regular salt-challenge (0.4% NaCl regular rat chow) from embryonic day 0.5 (E0.5) in Dahl Salt-sensitive hypertensive rat inducing hypertension-associated neutrophil/endothelial activation. Sub-endotoxic dose of LPS (1.8 mg/kg IV) was infused in study rats after observation of the 1 st intracerebral hemorrhage event in the age-matched rat cohort around 4m of age (signal ICH ~4m). After LPS was infused, treatment (Tx), either anti-DEspR mAb 10a3 or 6g8 as notated, or mock-treatment (mockTx) saline (vehicle) was given. Treated rats with full recovery were monitored until 35 days (35d). (B) Representative post-mortem images of rat brains after intravascular blood volume replaced with 1X PBS. Left, non-LPS-challenged brain; Middle: anti-DEspR (10a3) mAb treated brain after LPS-infusion. Right: LPS-challenge mock-treated control. (C) Kaplan-Meier survival curve of treated (Tx: 10a3, 1 mg/kg IV, n = 8) vs saline mock-treated (mockTx, n = 9) LPS-challenged hsICH rats. Log Rank Mantel-Cox test: P = 0.0007; hazard ratio (Mantel-Haenszel 10.2, 95% CI of ratio: 2.67 – 39.25). (D-G) Analysis of anti-DEspR mAb target engagement and bioeffects. Study groups are designated (+ or -) per agent (left to right): black open bar = control no LPS and no treatments, black bar = reference control LPS + saline, red bar = LPS + 10a3; red open bar = LPS + 6g8 (D) Minimal to no DEspR+ neutrophils in no-LPS rat control. Compared to LPS + saline control (100% reference), anti-DEspR mAbs 10a3 and 6g8 reduce survival of DEspR+ neutrophils (n = 6 replicates/group), concordant with target engagement and bioeffects in peripheral DEspR+ neutrophils ex vivo . (E) Brain membrane-bound protein levels of mouse-specific immunoglobulin (IgG) in 10a3 or 6g8 mAbs showing brain target engagement, 6g8 > 10a3. (F, G) Analyses of brain non-membrane bound proteins by ELISA detect reduced brain levels of (F) neutrophil-derived myeloperoxidase (MPO) in 10a3 and 6g8-treated rat brains compared to LPS + saline mockTx rat brain, and (G) reduced levels of albumin as a marker of edema in the brain. ng/g brain, nanogram per gram brain; μg/g brain, microgram per gram brain.
Techniques Used: Activation Assay, Ex Vivo, Enzyme-linked Immunosorbent Assay, Derivative Assay, Marker